Drug Profile


Alternative Names: Tabex

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator Sopharma
  • Developer Achieve Pharma
  • Class Antiparkinsonians; Neuroprotectants
  • Mechanism of Action Nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Smoking withdrawal

Highest Development Phases

  • Phase III Smoking withdrawal

Most Recent Events

  • 05 Jan 2017 Achieve Pharma plans a phase III trial in Smoking withdrawal
  • 18 Dec 2014 Phase-III clinical trials in Smoking withdrawal in New Zealand prior to December 2014 (PO)
  • 18 Dec 2014 Efficacy and adverse events data from the phase III CASCAID trial in Smoking withdrawal released by Extab
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top